Abstract Strategies for targeting adenomatous polyposis coli (APC) loss-of-function (APC-LOF) may provide an opportunity to intercept tumorigenesis in high-risk CRC patients, such as those with Familial Adenomatous Polyposis (FAP). Here, we uncovered a novel synthetic lethal dependency of APC-LOF on protein arginine methyltransferase (PRMT5).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile